Real-World data reveals how a common breast cancer drug is actually used
NCT ID NCT06495164
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study looks at medical records from routine care to see how Palbociclib (a targeted therapy) is used in people with a certain type of advanced breast cancer (HR+/HER2-). Researchers want to understand how long patients stay on treatment and whether it delays the need for chemotherapy. The study does not involve any new treatments or visits—it simply analyzes existing data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.